Why the study?
Does a CYP2C19 genotype-guided drug selection strategy improve net benefit in patients with ACS undergoing PCI compared to universal prasugrel or clopidogrel?
Does a CYP2C19 genotype-guided drug selection strategy improve net benefit in patients with ACS undergoing PCI compared to universal prasugrel or clopidogrel?
A CYP2C19 genotype-guided antiplatelet strategy offers a higher probability of greater net benefit compared to universal prasugrel or clopidogrel in patients with ACS undergoing PCI.
No takes yet. Share an insight, caveat, or question.
May support CYP2C19-guided antiplatelet selection in ACS-PCI; leaves open confirmation via randomized trials before practice change.
Guzauskas et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: